NVO SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Novo Nordisk A/S and a Lead Plaintiff Deadline of March 13, 2017

NEW YORK--()--The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Novo Nordisk A/S (NYSE: NVO) securities between April 30, 2015 and October 27, 2016.

Click here to learn about the case: http://www.wongesq.com/pslra/novo-nordisk-as. There is no cost or obligation to you.

According to the complaint, during the Class Period, Novo Nordisk issued materially false and misleading earnings and forecasts; said reports were inflated by collusive price fixing concerning the Company’s insulin drugs. The complaint further alleges that the Company misrepresented and concealed the true extent of the pricing pressures it was experiencing from pharmacy benefit managers.

If you suffered a loss in Novo Nordisk you have until March 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/novo-nordisk-as.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

The Law Offices of Vincent Wong
Vincent Wong, Esq., 212.425.1140
Fax. 866.699.3880
vw@wongesq.com

Release Summary

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced on behalf of investors who purchased Novo Nordisk A/S securities

Contacts

The Law Offices of Vincent Wong
Vincent Wong, Esq., 212.425.1140
Fax. 866.699.3880
vw@wongesq.com